Left Menu
Development News Edition

US STOCKS-Dow advances, S&P ekes out gain as vaccine timeline comes into focus

House Republican leader Kevin McCarthy, however, said he does not expect an agreement to be reached ahead of the Nov. 3 election as long as Pelosi is involved. The Dow Jones Industrial Average rose 112.11 points, or 0.39%, to 28,606.31, the S&P 500 gained 0.47 points, or 0.01%, to 3,483.81 and the Nasdaq Composite dropped 42.32 points, or 0.36%, to 11,671.56.

Reuters | Updated: 17-10-2020 01:55 IST | Created: 17-10-2020 01:55 IST
US STOCKS-Dow advances, S&P ekes out gain as vaccine timeline comes into focus

The S&P 500 posted a nominal gain on Friday as further clarity regarding the timeline for the development of a coronavirus vaccine and much better-than-expected retail sales data brought buyers back to the market. The Dow also joined the S&P in positive territory, both indexes snapping a three-day losing streak driven by halted vaccine trials and continued wrangling in Washington over a new pandemic relief package. But the Nasdaq ended the session lower.

Even so, they all posted gains on the week. Pfizer Inc announced it could apply for U.S. authorization for the COVID-19 vaccine it is developing with German partner BioNTech in November. Pfizer's stock gained 3.8%.

"The two highest-level market movers are the vaccine timeline and stimulus optimism," said Ross Mayfield, investment strategist at Baird in Louisville, Kentucky. "Sometimes the market gets a reality check that even if we get a vaccine early next year that's an incredibly aggressive and optimistic timeline." Retail sales in September blew past analyst expectations and consumer sentiment for the current month surprised to the upside, according to two separate economic reports. But with previous stimulus having run its course, the outlook is uncertain unless Washington can reach an agreement on a fresh round of fiscal aid.

"It's important from the retail sales data to see that the consumer is not just limping a long but exceeding expectations," Mayfield added. "I don't know how long this can continue without stimulus but it's heartening to see the consumer has held up pretty well despite some dire expectations." On the stimulus front, U.S. Treasury Secretary Steven Mnuchin told House Speaker Nancy Pelosi that President Donald Trump would "weigh in" with Senate Majority Leader Mitch McConnell if an agreement is reached on a new pandemic relief package. House Republican leader Kevin McCarthy, however, said he does not expect an agreement to be reached ahead of the Nov. 3 election as long as Pelosi is involved.

The Dow Jones Industrial Average rose 112.11 points, or 0.39%, to 28,606.31, the S&P 500 gained 0.47 points, or 0.01%, to 3,483.81 and the Nasdaq Composite dropped 42.32 points, or 0.36%, to 11,671.56. Of the 11 major sectors in the S&P 500, seven ended the session in the black. While utilities had the largest percentage gain, energy suffered the biggest loss.

Third-quarter reporting season burst from the starting gate this week, with 49 of the companies in the S&P 500 having reported. Of those, 86% have cleared the low bar set by expectations, according to Refinitiv. Oil services company Schlumberger NV posted its third straight quarterly loss due to falling crude prices and plunging demand. Its shares dropped 8.8%.

Railroad operator Kansas City Southern shed 2.7% and transportation and logistics company J.B. Hunt Transport Services Inc tumbled 9.7% after the companies' quarterly results were hit dropping shipping demand. The Dow Jones Transport index, considered a barometer of economic health, fell 1.3%.

Shares of fitness company Peloton Interactive Inc lost 3.7% after announcing a recall of faulty pedals on its popular exercise bikes. Declining issues outnumbered advancing ones on the NYSE by a 1.30-to-1 ratio; on Nasdaq, a 1.07-to-1 ratio favored decliners.

The S&P 500 posted 50 new 52-week highs and no new lows; the Nasdaq Composite recorded 98 new highs and 20 new lows. Volume on U.S. exchanges was 8.82 billion shares, compared with the 9.31 billion average over the last 20 trading days.


TRENDING

OPINION / BLOG / INTERVIEW

Farkhad Akhmedov: Calculating the price of impunity from the law

In insistences such as the battle over the Luna, Akhmedov has resorted to extreme legal machinations to subvert the High Courts decision and keep his assets from being seized. ...

Guinea’s elections hearken back to the autocracy and violence of its past

... ...

Pandemic-era FinCEN leaks ratchet up the urgency of lifting the veil on financial secrecy

As the coronavirus pandemic reverses decades of gains in combatting inequality, its more urgent than ever that authorities excise the dirty money that has metastasized within the financial systems guts....

CoE on Biomedical Engineering and e-Health: Catalyst to Transform Healthcare in Rwanda

A center of excellence in biomedical engineering, e-health, and allied fields can be of particular interest to Rwanda as it can act as a catalyst for transforming the countrys healthcare from one that is deficient in the provision and reach...

Videos

Latest News

Moody's cuts UK's debt rating on weak economic growth

Ratings agency Moodys lowered the United Kingdoms sovereign debt rating to Aa3 from Aa2 on Friday, citing weakening economic and fiscal strength. Negative long-term structural dynamics have been worsened by Britains decision to leave the Eu...

GLOBAL MARKETS-Pfizer vaccine hopes lift world stocks; dollar, gold on the defensive

Global shares bounced on Friday while safe havens such as the dollar were on the defensive as investors welcomed news that drugmaker Pfizer Inc could have a coronavirus vaccine ready in the United States by the end of this year. But concern...

France launches terrorism probe after teacher killed in knife attack

A man armed with a knife on Friday killed a middle school history teacher by slitting his throat in front of his school in a suburb of Paris, police said, in an attack that was being treated as terrorism. The attacker was shot dead by a pol...

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. That timeline ma...

Give Feedback